Start.Smart.Global 2019: ibidi Receives Valuable Funding to Enter the Japanese and Korean Life Science Market

(PresseBox) ( Munich, )
ibidi has been awarded valuable funding from BioM “Start.Smart.Global” to break into the challenging life science markets of Japan and Korea. They were one of only twelve ambitious European companies selected, which plan on expanding into these two Asian markets in 2020.

The funding includes a high-quality training course to optimize and accelerate specific market entry into Japan and South Korea. The training focuses on product regulations, culture complexity, access to customer networks, understanding market needs and the competition, as well as financing opportunities. Workshops and country roadshows will complete the market entry strategies.

“We are very pleased to benefit from this outstanding funding opportunity”, states Dr. Christian Leibold, Head of Sales at ibidi GmbH. “This training program will certainly help ibidi reach its ambitious goals for a continued expansion into Asia.”

Funded by the European Institute for Innovation & Technology (EIT) Health within the framework of its Accelerator program “GoGlobal”, the BioM cluster management agency in Martinsried, Germany developed the training project, “Start.Smart.Global”. It specifically targets start-ups and small- to medium-sized enterprises (SMEs), whose goal is to enter the Japanese and Korean life science markets.

Japan has the world’s second largest healthcare market and ranks amongst Europe’s top five pharmaceutical trading partners. South Korea is creating a culture of innovation with an attractive regulatory environment, in order to place itself among the top global health care hubs. Given Europe’s leading position in life sciences with novel technologies, services, and products, the Asian markets hold significant opportunities for innovative European SMEs. However, introducing complex, novel, and cutting-edge technologies can be time-consuming, tedious, and consultation-intensive for European health service and product companies. “Start.Smart.Global” will help speed up this process.

About EIT Health -

EIT Health is an independent community created in 2008 by the European Institute for Innovation & Technology (EIT). It aims to boost innovation and speed up entrepreneurship in Europe.

EIT Health´s Accelerator is a business-development program. With its GoGlobal projects, participating companies can obtain better knowledge about a local ecosystem, the special characteristics of the market, contacts and networking opportunities, and tailor-made training, all of which ease and accelerate the market entry into the target country. Different GoGlobal projects target a variety of non-European markets: Japan, South Korea, United States, China (Shenzhen and Hong Kong), Brazil, Israel, and Canada.


Since 1997, BioM  has been a network organization for the biotechnology sector in Munich and Bavaria, commissioned by the Bavarian Ministry of Economic Affairs. The development of innovative therapeutics and diagnostics, in particular for personalized healthcare, is the core competence of 270 companies in the region. BioM supports the Bavarian biotechnological and pharmaceutical sector with an extensive network aimed at developing new business contacts.

BioM manages a broad range of training sessions, events, and network meetings "by experts for experts". It also provides comprehensive consulting and specialized coaching, training, and mentoring programs for start-ups. In total, BioM has supported more than 200 start-up companies for 20 years.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an